MGX - Metagenomi Inc Common Stock Stock Price & Dividend Safety Sector: Healthcare | Exchange: NASDAQ Global Select Current Price & Safety Score Price: 0.80 USD StockBonds Safety Grade: F Altman Z-Score (Bankruptcy Risk): -3.65 StockBond Score: -3.56 Company Description Metagenomi Inc operates as a biotechnology company focused on gene editing committed to developing therapeutic solutions for patients The company utilizes a distinctive genome editing toolkit sourced from metagenomics for its development efforts within the United States This advanced toolkit comprises programmable nucleases base editors and sophisticated RNA and DNAmediated integration systems notably prime editing and CRISPRassociated transposases Metagenomi has established several key collaborations a strategic alliance with ModernaTX Inc to explore new genome editing systems for in vivo human therapeutic applications a development and licensing agreement with AffiniT Therapeutics Inc to create and commercialize geneedited Tcell receptor therapies for human cancer and a partnership with Ionis Pharmaceuticals Inc to research develop and market investigational medicines leveraging genome editing technologies Founded in 2016 the company is based in Emeryville California